Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Sep 26, 2023 7:45pm
232 Views
Post# 35655902

RE:RE:RE:RE:RE:RE:PanCan's Precision Promise adaptive clinical trial program

RE:RE:RE:RE:RE:RE:PanCan's Precision Promise adaptive clinical trial programThe ball is starting to roll. The shorts better start to cover or pay big time.
A $5 million grant? Not huge $$ BUT HUGE afirmation of the opportunity to move Pela forward.
About a month agao there was an institutional buy-in for $17 million.
Now $5 million from a grant.
These are larger outsiders doing a lot of due dilligence.

I expect yet another N.R. tomorrow am, before the fireside chat.
No idea what. So far this month has been full of surprises.
All of them good!

I did see a report a few days ago, the short trading was 62% that is veryhigh.
Could explain the dip & then recovery today.
PanCan are no fools. They have just came up to the table with $5million to add another opportunity.
MY read...no partnership.

Total buy-out, once phase 3 is underway.


<< Previous
Bullboard Posts
Next >>